Non replicating viral vector for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (excluding children) meta-analysis
ChAdOx1 phase 3 (AstraZeneca) NCT04400838		RCT	Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)	control	COVID-19 prophylaxis (excluding children)	some concern	5807/5829	conclusif	demonstrated 67 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
ENSEMBLE (COV3001) unpublished NCT04505722		RCT	Janssen AD26 vaccine (JNJ-78436735)	placebo	COVID-19 prophylaxis (excluding children)	some concern	21895/21888	conclusif	suggested 81 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias demonstrated 67 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias suggested 82 % decrease in hospitalization with a moderate degree of certainty due to some concern in risk of bias
27 studies excluded by filtering options (12 RCT / 15 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (excluding children) meta-analysis